Dihydrotanshinone I is the principal lipophilic phenanthioquinone compound found in Salvia miltiorrhiza Bunge, with antitumor properties [1]. Dihydrotanshinone I mainly induced intrinsic apoptosis mediated by regulation of Bcl-2 family proteins and activation of caspases, which included decreasing mitochondria membrane potential, inhibiting expression of anti-apoptotic protein such as Bcl-xL, Bcl-2[2]. Dihydrotanshinone I has been widely used to inhibit the growth of Gram-positive bacteria and to suppress the expression of pro-inflammatory genes[3].
In vitro, Dihydrotanshinone I significantly inhibited the proliferation of U-2 OS cells, HeLa cells, and NRK-49F cells after 24 hours of treatment, with IC50 values of 3.83μM, 15.48μM, and 25.00μM, respectively[4]. Treatment with 20μM Dihydrotanshinone I for 24 hours significantly induced apoptosis in HCT116 cells, accompanied by an increase in caspase-3/9 levels and the degradation of p62[5]. Treatment of MDA-MB-468 cells with 1μM Dihydrotanshinone I for 24 hours resulted in decreased expression of mesenchymal markers (such as vimentin, N-cadherin and active β-catenin), and inhibition of colony formation[6].
In vivo, Dihydrotanshinone I treatment via oral administration at a dose of 25mg/kg/day for three consecutive days alleviated the pathological changes of colitis in mice induced by dextran sulfate sodium salt (DSS), and inhibited the secretion of inflammatory cytokines[7]. Intraperitoneal injection of Dihydrotanshinone I (10mg/kg) was administered three times a week for 4 weeks, which inhibited the tumor growth in the MDA-MB-231 cell-xenograft mouse model[8].
References:
[1] Yue J, Hao D, Wang Y, et al. The multifaceted mechanisms of Dihydrotanshinone I in the treatment of tumors[J]. Biomedicine & Pharmacotherapy, 2024, 175: 116635.
[2] Chen X, Yu J, Zhong B, et al. Pharmacological activities of dihydrotanshinone I, a natural product from Salvia miltiorrhiza Bunge[J]. Pharmacological Research, 2019, 145: 104254.
[3] Jiang Z, Gao W, Huang L. Tanshinones, critical pharmacological components in Salvia miltiorrhiza[J]. Frontiers in Pharmacology, 2019, 10: 202.
[4] Fan L, Peng C, Zhu X, et al. Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U− 2 OS Cells through CD44 and Chemokine Signaling[J]. Molecules, 2022, 27(12): 3714.
[5] Wang L, Hu T, Shen J, et al. Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer[J]. Phytomedicine, 2015, 22(12): 1079-1087.
[6] Kashyap A, Umar S M, JR A D, et al. Dihydrotanshinone-I modulates epithelial mesenchymal transition (EMT) thereby impairing migration and clonogenicity of triple negative breast cancer cells[J]. Asian Pacific Journal of Cancer Prevention: APJCP, 2021, 22(7): 2177.
[7] Guo Y, Wu X, Wu Q, et al. Dihydrotanshinone I, a natural product, ameliorates DSS-induced experimental ulcerative colitis in mice[J]. Toxicology and applied pharmacology, 2018, 344: 35-45.
[8] Tsai S L, Suk F M, Wang C I, et al. Anti-tumor potential of 15, 16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis[J]. Biochemical pharmacology, 2007, 74(11): 1575-1586.
Dihydrotanshinone I是丹参中主要的一种脂溶性phenanthioquinone化合物，具有抗肿瘤特性[1]。Dihydrotanshinone I主要通过调控Bcl-2家族蛋白和激活caspase诱导内在凋亡途径，包括降低线粒体膜电位、抑制抗凋亡蛋白如Bcl-xL、Bcl-2的表达[2]。Dihydrotanshinone I已被广泛用于抑制革兰氏阳性菌的生长以及抑制促炎基因的表达[3]。
在体外，Dihydrotanshinone I处理24小时显著抑制了U-2 OS细胞、HeLa细胞和NRK-49F细胞的增殖，IC50值分别为3.83µM、15.48µM和25.00µM[4]。使用20µM的Dihydrotanshinone I处理24小时，显著诱导了HCT116细胞凋亡，并伴有caspase-3/9水平的升高和p62的降解[5]。用1µM的Dihydrotanshinone I处理MDA-MB-468细胞24小时，导致间充质标志物（如波形蛋白、N-钙黏蛋白和活性β-连环蛋白）表达下降，并抑制了克隆形成[4]。
在体内，每日口服给予25mg/kg剂量的Dihydrotanshinone I，连续三天，减轻了葡聚糖硫酸钠盐（DSS）诱导的小鼠结肠炎病理变化，并抑制了炎症细胞因子的分泌[7]。每周三次腹腔注射Dihydrotanshinone I（10mg/kg），持续四周，抑制了MDA-MB-231细胞异种移植小鼠模型中的肿瘤生长[8]。